Highlights From The Comments On CBT-i Apps

A compact Highlights companion to the CBT-i apps post: commenters surface cheaper CBT-i apps Scott had missed (Night Owl, Sleepedy, Dozy), he connects with Dozy's EA founder, and then handles the substance — effect sizes for in-person vs internet CBT-i (0.98 vs 0.51, both beating control), UpToDate's first-line endorsement, the app-economy's sub-$5 price ceiling problem, and a thoughtful worry about the FDA precertifying app 'therapeutics' at a lower evidence bar diluting what 'FDA-approved' signals.

Quality 64 · Strong. Strong, lower: a solid, useful companion with real evidence (effect sizes, first-line status) and a sharp regulatory observation, but thinner and less surprising than the richest companions. 64.

Claude’s paradigm shift 42 · Moderate. Moderate-slight: applies and sharpens existing evidence; the FDA-signaling point is a nice but small original angle. 42.

Real-world impact 1 · Negligible. Surfaces some real cheap-CBT-i options for readers; minor practical reach. RWI 1.